Science
that Strikes
the Right Chord

Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T cell products to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.

How We Target Specific B cells

Why “Cabaletta?"

A “cabaletta” is a rapid, repetitive, and technically challenging section of an operatic aria, designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development, building on our modular biologic platform that elegantly targets the cause of specific autoimmune diseases without the need for broad immunosuppression

Composing a New Cell Therapy Approach Beyond Established CAR T Therapeutics

Learn how engineered Chimeric AutoAntibody Receptor (CAAR) T cells were developed, building on the success of Chimeric Antigen Receptor (CAR) T therapies in cancer. Our lead candidate, DSG3-CAART, is now being evaluated in a clinical trial to treat pemphigus vulgaris, a rare and potentially deadly autoimmune blistering disease.

Posters & Publications

A Rapidly Expanding Collection of Targeted Cell Therapies

At Cabaletta, we are committed to transforming the treatment of B cell-mediated autoimmune diseases by utilizing our innovative and modular CAAR T platform to develop highly specific products that offer the potential for deep, durable and potentially curative responses for patients with autoimmune diseases.

DSG3-CAART for Patients with Mucosal Pemphigus Vulgaris

Our lead therapeutic program, DSG3-CAART, is designed to specifically target B cells that express autoantibodies to the cell adhesion protein desmoglein 3 (DSG3), which cause mucosal pemphigus vulgaris (mPV).

About DSG3-CAART

MuSK-CAART for Patients with MuSK-Associated Myasthenia Gravis

MuSK-CAART, our second product candidate, is designed to treat the subset of patients with MuSK-associated myasthenia gravis (MG) and targets B cells that express pathogenic autoantibodies against the MuSK protein, which is required for the formation and maintenance of the neuromuscular junction.

About MuSK-CAART

Putting Patients Center Stage

We’re on a mission to develop highly innovative and accessible cellular therapies with the potential to provide deep, durable, and potentially curative responses to patients by harnessing the power of the immune system. We aim to be their champions.

Our Focus: Patients

Developing Novel Treatments for Patients with Autoimmune Diseases

We are a clinical-stage biotechnology company working to develop and launch potentially breakthrough engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Email Alerts

Sign up for email alerts to stay informed and receive updates directly to your inbox.